A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)

Recruiting

Phase 3

SGT-003A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)

Sponsor:

Solid Biosciences Inc.

Code:

NCT07160634

Conditions

Duchenne Muscular Dystrophy

Eligibility Criteria

Sex: Male

Age: 7 - 11

Healthy Volunteers: Not accepted

Interventions

SGT-003

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-02-19. This information was provided to ClinicalTrials.gov by Solid Biosciences Inc. on 2026-02-03.